Core Insights - The high-pressure oxygen chamber concept has seen a decline of 0.21%, ranking among the top declines in concept sectors as of the market close on November 13 [1] - Within the sector, companies like Innovation Medical and International Medicine experienced significant declines, while six stocks saw price increases, with Dahu Co., Aoyang Health, and Samsung Medical leading the gains [1] Market Performance - The top-performing concept sectors today include: - Fluorochemical concept: +4.50% - Organic silicon concept: +4.47% - Sodium-ion battery: +4.47% - Lead metal: +4.27% - Phosphorus chemical: +4.25% [2] - The high-pressure oxygen chamber sector experienced a net outflow of 149 million yuan, with eight stocks seeing net outflows [2] Fund Flow Analysis - The stocks with the highest net outflows in the high-pressure oxygen chamber sector include: - Samsung Medical: -60.80 million yuan - Innovation Medical: -57.39 million yuan - International Medicine: -12.53 million yuan [2] - Conversely, the stocks with the highest net inflows include: - Yingkang Life: +10.12 million yuan - Hangyang Co.: +9.74 million yuan [2] Stock Performance - Key stock performances in the high-pressure oxygen chamber sector: - Samsung Medical: +0.37%, turnover rate: 2.18% - Innovation Medical: -2.00%, turnover rate: 13.41% - International Medicine: -0.80%, turnover rate: 1.13% [2]

Core Viewpoint - Jinling Pharmaceutical stated on November 12 that it will disclose information in accordance with the law, and investors should refer to the company's published announcements and periodic reports for relevant information [2] Summary by Category - **Company Information Disclosure** - The company will comply with legal requirements for information disclosure [2] - Investors are advised to check the company's announcements and periodic reports for detailed information [2]

Core Viewpoint - Jinling Pharmaceutical reported that as of November 10, 2025, the number of shareholders reached 33,417 [2] Company Summary - Jinling Pharmaceutical's shareholder count is projected to be 33,417 by November 10, 2025 [2]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in its quarterly report [2][21][42] - The third-quarter financial report has not been audited [3][10][11] - The company has made retrospective adjustments to its financial data due to a merger under common control [42][43][45] Financial Data - The company has undergone a retrospective adjustment of financial data due to the acquisition of additional shares in a medical investment fund, increasing its stake from 33.33% to 78.46% [42][43] - The adjustments will reflect in the consolidated profit and cash flow statements for the previous year [44] Shareholder Information - The company will hold its third extraordinary general meeting on November 13, 2025, with provisions for both on-site and online voting [50][51][52] - The meeting will address several proposals, including amendments to the company's articles of association and rules for shareholder meetings [27][29][30] Board and Supervisory Committee Actions - The board and supervisory committee have approved the retrospective adjustment of financial data and the third-quarter report [14][16][34][36] - The board has also approved the signing of a technology transfer contract [30]

Group 1 - The company signed a technology transfer contract with Nanjing Gulou Hospital for the transfer of technical secrets related to NK cell-specific antigens and tumor-specific antigen cell connectors, with a total contract amount of 78.5 million yuan (including tax) [6][10] - The payment structure includes an upfront fee of 1.5 million yuan, progress rewards totaling 2.5 million yuan, and sales sharing up to 74.5 million yuan based on future sales [10][11] - The transaction is not classified as a related party transaction and does not constitute a major asset restructuring as per relevant regulations [6][7] Group 2 - The technology involved aims to enhance the targeting ability of NK cells against tumors without the need for transfection, which is a significant advancement in biomedicine [9] - The contract allows the company to develop, produce, and sell products based on the transferred technology globally and indefinitely [13] - The company anticipates that this transaction will help expand its pipeline in the biopharmaceutical sector, aligning with its long-term strategic goals [17] Group 3 - The company held a board meeting on October 24, 2025, where it approved the signing of the technology transfer contract [6][20] - The company plans to revise its articles of association and related meeting rules, including the cancellation of the supervisory board, which will be replaced by the audit committee of the board [20][21] - The proposed changes to the articles of association and meeting rules will be submitted for approval at the upcoming third extraordinary general meeting of shareholders [20]

根据最新修订的《中华人民共和国公司法》《上市公司章程指引》 《上市公司股东会规则》等法律、法规、规范性文件的规定，结合金 陵药业股份有限公司（以下简称"公司"）实际情况，对原《股东大 会议事规则》进行修订，将其名称调整为《股东会议事规则》，修订 前后内容对照如下： | 序 | 修订前的内容 | 修订后的内容 | | --- | --- | --- | | 号 | | | | 1 / | | 第二条 公司股东会的召集、提案、通知、 召开等事项适用本规则。 | | | 第二条 股东大会分为年度股东大会 | | | | 和临时股东大会。年度股东大会每年 | 第三条 股东会分为年度股东会和临时 | | | 召开一次，并应当于上一个会计年度 | 股东会。年度股东会每年召开一次，应 | | | 结束后的 6 个月内举行。临时股东大 | 当于上一个会计年度结束后的 6 个月内 | | | 会不定期召开，出现《公司法》第一 | 举行。临时股东会不定期召开，出现《公 | | | 百条规定的应当召开临时股东大会的 | 司法》第一百一十三条规定的应当召开 | | | 情形时，临时股东大会应当在 2 个月 | 临时股东会的情形时，临 ...

金陵药业股份有限公司 章程 二零二五年十月 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东会 | 6 | | 第一节 | 股东的一般规定 | 6 | | 第二节 | 控股股东和实际控制人 | 8 | | 第三节 | 股东会的一般规定 | 8 | | 第四节 | 股东会的召集 | 10 | | 第五节 | 股东会的提案与通知 | 11 | | 第六节 | 股东会的召开 | 12 | | 第七节 | 股东会的表决和决议 | 14 | | 第五章 | 董事会 | 17 | | 第一节 | 董事的一般规定 | 17 | | 第二节 | 董事会 | 20 | | 第三节 | 独立董事 | 24 | | 第四节 | 董事会专门委员会 | 26 | | 第六章 | 高级管理人员 | 27 | | 第七章 | 党委 | 29 | | 第一节 | 党组织的机构设置 | 29 | ...

金陵药业股份有限公司股东会议事规则 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一个会计年度结束后的 6 个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条规定的应当召开临时股东会的情形时，临时股东会应当在 2 个月内召开。 公司在上述期限内不能召开股东会的，应当报告中国证券监督管理委员会江 苏监管局（以下简称江苏证监局）和深圳证券交易所，说明原因并公告。 第五条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第六条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第七条 公司召开股东会，应当聘请律师对以下问题出具法律意见并公 告： 第一章 总则 第一条 为进一步明确金陵药业股份有限公司（以下简称公司）股东会的职 责权限，规范股东会运作，提高股东会议事效率，保证股东会会议程序及决议的 合法性，更好地维护公司股东的合法权益， ...

第二章 董事会 第三条 公司董事会由九名董事组成，其中独立董事为三名，职工代表董事 一名。董事会设董事长一名，可以设副董事长，董事会秘书一名。董事会办公室 （战略研究部）为董事会日常办事机构。 董事长和副董事长由董事会由全体董事过半数选举产生，董事会秘书由董事 长提名，经董事会决议通过。 第四条 董事会行使下列职权： （一）召集股东会，并向股东会报告工作； 金陵药业股份有限公司董事会议事规则 第一章 总则 第一条 为了规范金陵药业股份有限公司（以下简称"公司"）董事会的议 事方法和程序，确保董事会高效运作科学决策，切实行使董事会的职权，根据《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》及 《金陵药业股份有限公司章程》（以下简称《公司章程》）等有关规定，制定本 规则。 第二条 本规则对公司全体董事、董事会秘书、列席董事会会议的其他有关 人员都具有约束力。 （二）执行股东会的决议； （三）决定公司的发展战略和规划、经营计划和投资方案； （四）审议批准公司的年度财务预算方案、决算方案； （五）制订公司的利润分配方案和弥补亏损方案； （六）制订公司增加或者减少注册资本、发行债券或者其他证券 ...

| | （四）二分之一以上独立董事提议时； | 时； | | --- | --- | --- | | | （五）监事会提议时； | （四）二分之一以上独立董事提议 | | | （六）总裁提议时。 | 时； | | | | （五）审计委员会提议时； | | | | （六）总裁提议时。 | | | 第十条 各应参加会议的人员接到会 | | | | 议通知后，应在开会日期的前二天告 | | | | 知董事会秘书是否参加会议。 | 第十条 各应参加会议的人员接到 | | | 任何董事可放弃要求获得董事会会议 | | | 7 | 通知的权利。 | 会议通知后，应在开会日期的两日前 | | | 董事未在到会前或到会时提出未收到 | 告知董事会秘书是否参加会议。 | | | 会议通知的异议，应视作已向其发出 | | | | 会议通知。 | | | | 第十三条 公司的股东、董事、监事、 | | | | 总裁等需要提交董事会研究、讨论、 | | | | 决议的议案应预先提交董事会秘书， | | | | 由董事会秘书汇集分类整理后交董事 | 第十三条 公司的股东、董事、审计 | | | 长审阅，由董事长决定是否列入议程。 | ...